Woodline Partners’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
Other funds holding ARCT
AIM
NAMA
VCM
VPM
Woodline Partners's ARCT Position: Q1 2026 in Review
Woodline Partners sold out of Arcturus Therapeutics (ARCT) in Q1 2026, closing a stake of 66,577 shares — an estimated $408K sold.
Woodline Partners first reported a position in ARCT in Q2 2020 and held it in 17 quarters. The position peaked at $33.7M in Q4 2023. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.
- Woodline Partners reported no remaining Arcturus Therapeutics position as of Q1 2026 after selling out during the quarter.
- Woodline Partners sold 66,577 Arcturus Therapeutics shares in Q1 2026, an estimated $408K.
- Woodline Partners first reported a position in Arcturus Therapeutics in Q2 2020 and held it in 17 quarters.
- Woodline Partners's Arcturus Therapeutics position peaked at $33.7M in Q4 2023.
- 124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.
Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.